Dermatology biotech Biofrontera files for a $22 million IPO
Biofrontera, which sells treatments for skin conditions caused by sun damage, filed on Friday with the SEC to raise up to $22 million in an initial public offering.
The Germany-based company was founded in 1997 and booked $12 million in sales for the 12 months ended June 30, 2017. It plans to list on the Nasdaq under the symbol BFRA. Biofrontera filed confidentially on October 4, 2017. The Benchmark Company is the sole bookrunner on the deal. No pricing terms were disclosed.
The article Dermatology biotech Biofrontera files for a $22 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.